CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Fosamprenavir +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00028366
NCT00028366N/ACompleted
CompareCT.gov

A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected Subjects With Virologic Treatment Failure

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 28, 2001·Updated Nov 1, 2021

In Brief

A clinical study evaluating Fosamprenavir, Lopinavir/Ritonavir, and 2 other interventions for HIV Infections. Completed, across 13 sites.

Detailed Summary

Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study also will compare the effectiveness, safety, tolerability, and drug levels in the blood of these anti-HIV drug combinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2001
Study CompletionJul 1, 2005
TodayJul 2, 2026
Posted 24.5 years ago

Interventions

Fosamprenavirdrug

Lopinavir/Ritonavirdrug

Ritonavirdrug

Tenofovir disoproxil fumaratedrug